BRNS
Barinthus Biotherapeutics plcNASDAQHealthcare$0.60-1.03%ClosedMarket Cap: $24.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.31
P/S
0.00
EV/EBITDA
0.61
DCF Value
$1.48
FCF Yield
-206.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-70.6%
ROA
-67.7%
ROIC
-59.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $4.8M | $-11.1M | $-0.27 | — |
| FY 2025 | $0.00 | -Infinity% | $-54.2M | $-66.4M | $-1.64 | — |
| Q3 2025 | $0.00 | NaN% | $-15.1M | $-14.6M | $-0.36 | — |
| Q2 2025 | $0.00 | NaN% | $-23.3M | $-21.1M | $-0.52 | — |
| Q1 2025 | $0.00 | NaN% | $-20.6M | $-19.6M | $-0.49 | — |
| Q4 2024 | $0.00 | NaN% | $-23.4M | $-20.5M | $-0.51 | — |
| FY 2024 | $15.0M | 100.0% | $-68.0M | $-61.1M | $-1.55 | — |
| Q3 2024 | $15.0M | 100.0% | $-9.4M | $-8.1M | $-0.21 | — |
| Q2 2024 | $0.00 | NaN% | $-18.3M | $-16.9M | $-0.43 | — |
| Q1 2024 | $0.00 | NaN% | $-16.9M | $-15.5M | $-0.40 | — |
| Q4 2023 | $0.00 | NaN% | $-20.0M | $-17.3M | $-0.45 | — |
| FY 2023 | $802.0K | 100.0% | $-83.9M | $-73.3M | $-1.91 | — |